BioCryst Pharmaceuticals (CH:BO1)
NASDAQ:BO1
BO1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
ORLADEYO Commercial TractionSustained new prescription trends and retention (monthly prescriber additions ~60; ~60% one-year retention) plus reiterated 2026 revenue guidance ($625–$645M) create a durable, recurring revenue base. This supports scaled commercialization and predictable cash conversion over the next several quarters.
Material Improvement In Cash GenerationSharp, sustained positive operating and free cash flow materially increases self-funding capacity for operations, R&D and business development. Better cash generation reduces near-term refinancing dependence and gives management optionality to fund pipeline progression and commercial investments.
Pipeline Progress And BD That Derisks GrowthCompletion of a pivotal Phase 3 and compelling attack-reduction data materially derisk navenibart's clinical profile and U.S. filing timeline. Coupled with a European license (upfront, milestones, royalties), this diversifies medium-term revenue potential beyond ORLADEYO and preserves upside via milestones.
Bears Say
Persistent Negative Shareholders' EquityDespite meaningful debt reduction, negative shareholders' equity is a structural capital-structure weakness that reduces buffer against shocks and complicates refinancing or covenant flexibility. Over months this elevates insolvency sensitivity and limits strategic optionality compared with healthier equity bases.
Acquisition-related GAAP Charge, Dilution And LeverageThe Astria transaction produced a large non-cash GAAP charge and substantial share issuance, materially diluting equity and complicating GAAP earnings comparability. Combined with a $400M senior credit facility, the deal raises structural leverage and per-share dilution risks that will affect investor returns for quarters to come.
Pediatric Manufacturing And Launch Execution RiskA production problem delaying pediatric pellet fulfillment introduces execution risk for converting strong pediatric demand into paid sales. Delays can push out revenue diversification, increase costs to remediate manufacturing, and weigh on commercial momentum through the upcoming quarters.
BioCryst News
BO1 FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is BioCryst Pharmaceuticals’s market cap?
Currently, no data Available
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 34 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$2.328 earnings per share for the quarter, missing the consensus estimate of $0.034 by -$2.362.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 0.12.
How many shares outstanding does BioCryst Pharmaceuticals have?
Currently, no data Available
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of -$2.328 in its last earnings report, missing expectations of $0.034. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:BO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.94 (― Downside)
$18.94 (― Downside)
Insider Transactions
Sold Shares
Worth CHF489.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.70%
12-Months-Change
Fundamentals
Return on Equity
123.57%
Trailing 12-Months
Asset Growth
-3.12%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BO1 Company Deck
BO1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and progressing late-stage and early-stage pipeline programs, with double-digit revenue and operating profit growth on a non-GAAP basis, meaningful licensing and financing activity that bolsters liquidity, and positive clinical momentum for navenibart and BCX17725. Key negatives include a manufacturing delay for the pediatric pellet fulfillment (timing uncertain), a large GAAP in-process R&D charge of $698M from the Astria acquisition, increased R&D spend and financing/dilution to fund the deal, and ongoing competitive entrants in the HAE market. Management maintained 2026 guidance and emphasized confidence in ORLADEYO demand and pipeline execution.View all CH:BO1 earnings summariesBO1 Stock 12 Month Forecast
Average Price Target
$18.94
Options Prices
Currently, No data available
---